Bronchogen (AEDL)

AEDL Tetrapeptide | Bronchial Bioregulator

Weight: 432 Da
Half-life: Minutes (short peptide); effects persist via epigenetic changes
Chain: 4 amino acids
3 studies
2020 latest
Moderate Research
Dose 10-20 mg oral or 10 mg injectable
Frequency Daily for 10-20 days per cycle
Cycle 10-20 days
Storage Oral capsules: room temperature. Injectable: 2-8°C refrigerated

Community Research

Join others researching Bronchogen — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Bronchogen is a Khavinson bioregulator tetrapeptide (AEDL) with primary effects on the bronchopulmonary system. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology by Professor Vladimir Khavinson, it targets bronchial tissue and supports respiratory function. Like other Khavinson peptides, Bronchogen penetrates cell nuclei to influence gene expression related to respiratory tissue maintenance and repair.

Mechanism of Action

Bronchogen works through epigenetic regulation by penetrating cell and nuclear membranes to interact with DNA and modulate gene expression in bronchial tissue. It regulates protein synthesis in bronchopulmonary cells, supporting maintenance and repair of respiratory epithelium. The tetrapeptide structure allows efficient cellular uptake and tissue-specific targeting to bronchial structures.

01 Supports bronchial tissue function
02 Regulates protein synthesis in lungs
03 Targets bronchopulmonary system
04 Maintains respiratory epithelium
05 Part of Khavinson bioregulator family
06 Epigenetic mechanism of action
07 Tissue-specific targeting
08 Well-tolerated in research

Molecular Data

Molecular Weight
432 Da
Chain Length
4 amino acids
Type
Tetrapeptide bioregulator
Amino Acid Sequence
One-letter: AEDL
H₂N
A 1
O ‖ C
N
E 2
O ‖ C
N
D 3
O ‖ C
N
L 4
COOH
Ala
1

Alanine

Position 1

Glu
2

Glutamic Acid

Position 2

Asp
3

Aspartic Acid

Position 3

Leu
4

Leucine

Position 4

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Research Indications

Respiratory Support
Bronchial Function effective

Supports bronchial tissue through gene expression regulation.

Respiratory Maintenance moderate

Helps maintain respiratory epithelium health.

Pulmonary Health moderate

Regulates protein synthesis in lung tissue.

Anti-Aging
Respiratory Aging moderate

Addresses age-related changes in bronchial tissue.

Gene Expression moderate

Modulates gene expression in respiratory cells.

Dosing Protocols

Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles.

GoalDoseFrequencyRoute
Standard protocol10-20 mgDaily for 10-20 daysOral capsules
Maintenance10 mg2-3 cycles yearlyOral capsules

Interactions

++
Chonluten
Related respiratory bioregulators; complementary mechanisms.
synergistic
++
Epitalon
Often combined in comprehensive anti-aging Khavinson protocols.
synergistic
+
Crystagen
Both have immune-modulating properties; different tissue targets.
compatible
+
Vilon
Part of Khavinson bioregulator family; targets different tissue.
compatible

What to Expect

During cycle
Gene expression modulation begins
Post-cycle
Effects persist due to epigenetic changes
Weeks-Months
Respiratory function improvements
Long-term
Cumulative benefits with periodic cycles

Side Effects & Safety

Common Side Effects

  • Generally well-tolerated
  • Minimal side effects reported

Stop Signs - Discontinue if:

  • Allergic reactions
  • Unusual respiratory symptoms

Contraindications

  • Active respiratory emergencies (seek medical care)
  • Known hypersensitivity
  • Pregnancy or breastfeeding

Quality Checklist

Good Signs

  • White powder or capsules
  • Clear solution if reconstituted
  • Proper packaging and labeling

Warning Signs

  • Unknown source or purity

Bad Signs

  • Discoloration
  • Unusual odor
  • Damaged packaging

References

  • Khavinson Peptide Bioregulators
    Advances in Gerontology (2020)

    Comprehensive review of bioregulator peptides including respiratory bioregulators.

  • Short Peptides and Bronchial Function
    Bulletin of Experimental Biology and Medicine (2018)

    Tetrapeptides derived from bronchial tissue regulate protein synthesis in respiratory cells.

  • Bioregulator Peptides and Respiratory Health
    Cell Technologies in Biology and Medicine (2016)

    Short peptides support bronchopulmonary system through epigenetic mechanisms.

Related Peptides

Chonluten synergistic

Related respiratory bioregulators; complementary mechanisms.

Epitalon synergistic

Often combined in comprehensive anti-aging Khavinson protocols.

Crystagen compatible

Both have immune-modulating properties; different tissue targets.

Vilon compatible

Part of Khavinson bioregulator family; targets different tissue.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.